P2908 - Impact of Sarcopenia on Outcomes in Cirrhotic Patients: Nationwide Inpatient Sample Study 2016-2020

Vikash Kumar, MD¹, Sahiljot Bhupal, MBBS², Rahul Kumar, MD³, Naresh Kumar, MD⁴, Sunny Kumar, MD⁵, Shamsa M. Qaadri, BSc⁶, Amelia Panjwani, BSc⁶, Diksha Kajal, MD,⁷, Aakash Aakash, MD⁸, Aalam Sohal, MD^9
1Creighton University School of Medicine, Brooklyn, NY; ²Dayanand Medical College and Hospital, Chicago, IL; ³Jacobi/ North Central Bronx Hospital Bronx, Bronx, NY; ⁴The Brooklyn Hospital Center, Brooklyn, NY; ⁵The Wright Center for GME, Scranton, PA; ⁶St. George's University School of Medicine, Brooklyn, NY; ⁷Florida State University College of Medicine, Cape Coral, FL; ⁸Florida State University Cape Coral Hospital, Cape Coral, FL; ⁹Creighton University School of Medicine, Seattle, WA

Introduction: Sarcopenia involves the loss of muscle mass and function is a significant concern for patients with cirrhosis. This population is especially vulnerable to sarcopenia due to factors like malnutrition, metabolic problems, and chronic inflammation. Recognizing the demographic, clinical and hospital-related factors associated with sarcopenia in cirrhotic patients, as well as its impact on patient outcomes is essential for guiding further studies and developing prevention strategies.

Methods: A retrospective analysis was performed by utilizing the NIS database 2016 -2020 and the International Classification of Diseases, Tenth Revision codes to identify the patients > 18 years old with the principal diagnosis of cirrhosis. Effect of sarcopenia was studied on mortality, morbidity, and resource utilization. Categorical variables were compared using the chi-square test, and continuous variables were compared using the t- test. Multivariable regression analyses were performed adjusting for demographics, hospital-level characteristics, and relevant comorbidities.

Results: We identified a total of 11,447,989 patients with Cirrhosis in 2016-2020, Of whom 19.5% (2,239,255) had Sarcopenia. Sarcopenia prevalence was highest in individuals over 65 (62.1%) and was significantly associated with African American race (16.8%) and Asian/Pacific Islanders (3.3%) ( Table 1). Clinically, sarcopenia was associated with higher rates of hepatic encephalopathy (63.5%), ascites (2.9%), and hepatocellular carcinoma (2.1%). Outcome analysis showed that sarcopenic patients had higher in-hospital mortality (14.1%, OR = 1.67), ICU admission rates (18.3%, OR = 1.42), and acute kidney injury (44.5%, OR = 1.29). They also required more renal replacement therapy (8.7%, OR = 1.07) and had a greater likelihood of home discharge (80.0%, OR = 2.35). Additionally, sarcopenia was associated with significantly longer hospital stays (mean 11.67 days vs 7.11 days, p < 0.001) and higher total charges (mean $140,874.40 vs $84,829.53, p < 0.001).

Discussion: Sarcopenia has a profound impact on patients with cirrhosis, leading to higher mortality rates, longer hospital stays, and increased healthcare costs. Recognizing these clinical implications highlights the urgency of identifying sarcopenia early and implementing effective interventions to enhance patient care and outcomes for this vulnerable group



Disclosures:


Vikash Kumar, MD¹, Sahiljot Bhupal, MBBS², Rahul Kumar, MD³, Naresh Kumar, MD⁴, Sunny Kumar, MD⁵, Shamsa M. Qaadri, BSc⁶, Amelia Panjwani, BSc⁶, Diksha Kajal, MD,⁷, Aakash Aakash, MD⁸, Aalam Sohal, MD⁹. P2908 - Impact of Sarcopenia on Outcomes in Cirrhotic Patients: Nationwide Inpatient Sample Study 2016-2020, ACG 2024 Annual Scientific Meeting Abstracts. Philadelphia, PA: American College of Gastroenterology.